Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 1,001–1,002 of 1,002
Malcolm, D. W., Sorrells, J. E., Van Twisk, D., Thakar, J., & Benoit, D. S. W. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10035 · Cited by 15
“Furthermore, TLR activation in hMSCs has been shown to stimulate secretion of immunomodulatory cytokines and chemokines, such as CCL2, TNF, and multiple interleukins.51,53 RIG-I signaling, which is associated with the immune response, was activated in MSCs after delivery of a double stranded miRNA-145 mimic using Lipo…”
BackgroundInfluentialSteinrigl, A., Nosek, D., Ertl, R., Günzburg, W. H., Salmons, B., & Klein, D. (2007) · Virology · doi:10.1016/j.virol.2006.11.037 · Cited by 13
“The ability to stably integrate transgenes was the initial driving force behind development of retroviral and lentiviral vectors for gene therapy applications (Thomas et al., 2003).”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.